Significance
G protein-coupled receptors regulate several physiological processes, many of which sense nutrients. The mode of action of these nutrients remains elusive, as it is difficult to control nutrient concentrations around living cells. The calcium-sensing receptor is regulated by multiple factors, including ions and amino acids, to control calcium homeostasis; and genetic mutations are responsible for human diseases. Here, we investigated this receptor in a perfect control of ambient nutrients. Based on the identification of calcium ion activation sites, we propose a molecular basis for how calcium and amino acids cooperate to control receptor activation. This leads to a model for the mechanism of activation of this receptor and its modulation by multiple ligands and genetic mutations.
Keywords: G protein-coupled receptor, allosteric modulator, calcium, amino acids, nutrient sensing
Abstract
Many membrane receptors are regulated by nutrients. However, how these nutrients control a single receptor remains unknown, even in the case of the well-studied calcium-sensing receptor CaSR, which is regulated by multiple factors, including ions and amino acids. Here, we developed an innovative cell-free Förster resonance energy transfer (FRET)-based conformational CaSR biosensor to clarify the main conformational changes associated with activation. By allowing a perfect control of ambient nutrients, this assay revealed that Ca2+ alone fully stabilizes the active conformation, while amino acids behave as pure positive allosteric modulators. Based on the identification of Ca2+ activation sites, we propose a molecular basis for how these different ligands cooperate to control CaSR activation. Our results provide important information on CaSR function and improve our understanding of the effects of genetic mutations responsible for human diseases. They also provide insights into how a receptor can integrate signals from various nutrients to better adapt to the cell response.
Cells have to constantly adapt to their environment and, as such, sense through specific receptors, a large number of nutrients, such as ions, l-amino acids (l-AAs), glucose, various metabolites, and lipids (1). Despite the importance of such processes, how one receptor senses various nutrients remains elusive, as it is difficult to control nutrient concentrations around living cells.
G protein-coupled receptors (GPCRs) form the largest family of membrane receptors and major drug targets (2). Many of them are activated or modulated directly by nutrients (3, 4). Among GPCRs, the calcium-sensing receptor (CaSR) is a prototypical nutrients sensory receptor activated or modulated by both calcium (5) and amino acids (6), but also by endogenous and exogenous compounds such as different cations, polyamines, polypeptides, and aminoglycoside antibiotics (7, 8) (Fig. 1A).
Fig. 1.
A conformational FRET-based sensor to investigate the structural dynamics of the CaSR ECD. (A) Orthosteric binding sites for calcium remain unclear and controversial. Many genetic mutations have been found in patients with calcemic disorders, and they are located in the different regions of the receptor. Besides, autoantibodies have been identified in rare autoimmune diseases. (B) Crystal structures of the extracellular domain of class C GPCR dimers in the resting forms (Left, CaSR PDB 5K5T biological assembly 2, mGluR5 PDB 6N52, and GABABR PDB 4MQE) and in the active forms in the presence of l-Trp, l-quisqualate, or GABA (Right, CaSR PDB 5K5S, mGluR5 PDB 6N51, and GABABR PDB 4MS3, respectively). The residues used to measure distances [D23 for CaSR, R26 for mGluR5, R50 for GABAB1b (Right) and S53 for GABAB2 (Left), respectively] are highlighted as orange spheres. (C) Cartoon illustrating the full-length SNAP-CaSR labeled with the Lumi4-Tb donor and the green fluorescent acceptor, with high FRET signal in the absence of agonist and a lower FRET signal in the presence of agonist. (D) FRET signal between the two VFTs after cell surface labeling of SNAP-CaSR-expressing cells with fluorophores as indicated in C, in the presence of a saturating concentration of calcium (20 mM CaCl2, injection at t = 30 s) and after calcium removal (t = 60 to 90 s). Data are mean ± SEM of a typical experiment performed in replicates. The control with 20 mM CaCl2 (dotted red line) or buffer alone (dotted blue line) are shown for the same period of time (0 to 90 s). (E–H) Correlation (H) between the potencies (pEC50) of different agonists on CaSR determined by FRET sensor assay (E), inositol monophosphate (IP1) accumulation assay (F), and intracellular calcium (Ca2+i) release assay (G). Data in E–G are mean ± SEM of at least three independent experiments performed in triplicates and normalized to the maximum response of CaCl2. Data in H are mean ± SEM from the fitted curves for each individual experiment in E–G. (I) FRET signal measured for CaCl2 in the presence of either PAM (10 μM NPS R-568) or NAM (10 μM NPS 2143). Data are mean ± SEM of at least three independent experiments performed in triplicates and normalized to the maximum response of the control. (J) FRET signal measured for the indicated mutants in the absence or presence of 20 mM CaCl2. Data are mean ± SEM of at least three independent experiments performed in triplicates and normalized to WT. Data are analyzed using two-way ANOVA with Tukey’s multiple comparisons test to determine significance, with ****P ≤ 0.0001.
CaSR is essential in the parathyroid gland for maintaining extracellular calcium homeostasis (5). It is also expressed in other tissues such as bone, gut, kidney, and brain (5, 9), where it has additional effects. Many genetic mutations that lead to loss or gain of function of the CaSR, have been identified in patients with metabolic syndromes (9, 10). In addition, CaSR autoantibodies that modify the signaling properties of the receptor have been identified in rare diseases (11). Finally, CaSR is the target of three commercial drugs acting as a positive allosteric modulator (PAM). Etelcalcetide (12, 13) targets the extracellular domain, while cinacalcet (14, 15) and evocalcet (16) bind to the transmembrane domain.
CaSR belongs to class C GPCRs, most of which are activated by l-AAs or derivatives that bind to the conserved extracellular Venus flytrap (VFT) binding domain, such as the mGlu, GABAB, GPCR6A, and umami taste receptors, as well as the fish olfactory receptors and some pheromone receptors (17). These receptors form obligatory dimers, providing a unique mode of activation compared to GPCRs from other classes. Like most class C GPCRs, each subunit of the CaSR homodimer is composed of an extracellular domain (ECD), made up of a VFT and a cysteine-rich domain (CRD) connected to a heptahelical transmembrane (7TM) domain, responsible for G protein coupling (Fig. 1A). Numerous studies have been performed with the aim to understand the molecular basis of calcium ion and amino acid actions at the CaSR (18). Recent crystal structures of the isolated ECD have been solved in the absence or presence of calcium and amino acids by two different groups (19, 20) (Fig. 1B), but how the binding of these nutrients in this domain triggers receptor activation remains elusive.
These solved CaSR structures led to the proposed rearrangement of the ECD dimer upon activation (19). This rearrangement is limited to the closure of both VFTs upon Ca2+ binding, without a major reorientation of the VFTs (Fig. 1B). This is in contrast to what has been observed with the closely related mGlu receptors, for which the closure of the VFTs results in a major reorientation of the VFTs (21–24) (Fig. 1B). However, this CaSR model appears similar to what was observed with the distantly related GABAB heterodimer (25, 26) (Fig. 1B), but this needs to be firmly documented with the full-length CaSR.
CaSR structures also revealed in much detail the l-AAs binding mode, but the Ca2+ sites involved in receptor activation remain unclear, especially due to the limited resolution of the structures. The two studies reporting CaSR structures eventually did not propose the same Ca2+ sites (SI Appendix, Fig. S1 A and B). The molecular basis for l-AA activity was also difficult to characterize in functional studies using cell-based assays, due to the ambient concentrations of ions and other nutrients including l-AAs that are difficult to control tightly.
In this study, we have developed an innovative assay to clarify the conformational changes occurring during CaSR activation, and to investigate how nutrients control this activation. We have set up a time-resolved Förster resonance energy transfer (TR-FRET) conformational CaSR biosensor that enables work in cell-free conditions, where the nutrient concentrations can be well controlled (SI Appendix, Fig. S2). Using this assay, we demonstrate that calcium ions are sufficient to stabilize the active state of the receptor, while l-AAs have no effect on their own but enhance the effect of Ca2+ then acting as pure PAMs. Moreover, we show that chloride ions identified in the CaSR structures also act as PAMs, potentiating the effect of Ca2+. We propose a model with two separate binding sites for calcium ions in each CaSR VFT, allowing an indirect interaction of both Ca2+ ions with the l-AA.
Results
Development of a FRET-Based Conformational Sensor for the CaSR.
In order to better understand the mode of action of various ligands of the CaSR, we first aimed to clarify the conformational changes associated with its activation. We developed a TR-FRET-based conformational biosensor using an approach previously reported to examine conformational changes in mGlu and GABAB receptors (21, 24). The CaSR subunit was fused at its N terminus with a SNAP-tag that can be covalently labeled with fluorophores using specific cell-impermeant substrates (27) (Fig. 1C). In the absence of agonists, a high signal is measured between the two SNAP-tags of the CaSR dimer (Fig. 1D). Upon calcium addition, a large and fast decrease in FRET signal was observed, and the high FRET signal was restored with a calcium-free buffer (Fig. 1D). Accordingly, the fluorescence decay of the donor, measured through the fluorescence decay of the sensitized acceptor, becomes slower in the presence of calcium (SI Appendix, Fig. S3A). It revealed a lower FRET efficiency between the donor and acceptor due to a larger distance between them in the presence of an agonist. Finally, since the TR-FRET signal is mostly dependent on the distance between the donor and the acceptor, the strong decrease of FRET revealed a large increase in distance between the two N-terminal SNAP-tags during activation. A similar increase of distance between the two N-terminal SNAP-tags was observed in FRET-based conformational mGluR biosensors (21, 24), but not in the GABAB receptor (28).
To prove that the change in TR-FRET signal reflects receptor activation, we analyzed the effect of different CaSR agonists. They all consistently induced a decrease in FRET efficiency with potencies (fitted pEC50) in the range of those measured using cellular functional assays: the inositol phosphate (IP1) accumulation and intracellular calcium (Ca2+i) release assays (Fig. 1 E–H and SI Appendix, Fig. S3 B–D). Such movement of the ECDs should also be affected by allosteric modulators acting in the 7TM domain (21) (SI Appendix, Fig. S3E). As expected, two commercial allosteric modulators of the CaSR, NPS R-568 (29) and NPS 2143 (30), which are positive and negative allosteric modulators, respectively, were found to influence the agonist-induced changes in TR-FRET. While NPS 2143 decreased agonist potencies, NPS R-568 enhanced agonist potencies in the TR-FRET assay (Fig. 1I). These data are perfectly in line with the results obtained from the IP1 functional assay (SI Appendix, Fig. S3F). Finally, we show that G protein coupling favors the rearrangement of the ECDs, consistent with the allosteric effect of the G protein that favors the active state of GPCRs (31). Accordingly, overexpression of the Gαq subunit, known to couple to the CaSR (8), reduced basal FRET signal (SI Appendix, Fig. S3I). Of note, nonhydrolyzable GTPγS that uncouples G proteins to GPCRs (31) had no effect (SI Appendix, Fig. S3J), most probably due to the low abundance of Gq in the membrane preparations used in this assay, as the Gαq type of G proteins is not myristoylated (32).
Altogether, our data show that the CaSR dimer undergoes a large conformational change of the VFTs during activation, compatible with a relative reorientation of VFT dimer. This conformational change can be used to monitor the activation of the receptor and to analyze the effects of ligands including allosteric modulators.
FRET Sensor to Detect the CaSR Conformation Stabilized by Mutations.
To further validate our sensor, we introduced mutations in regions of the receptor known to control its active state. We show that the A843E7.38 genetic and gain-of-function mutation (33) in the transmembrane domain 7 (TM7) which induced autosomal dominant hypocalcemia, stabilized the active state of the ECD as revealed by the low FRET signal (Fig. 1J), without changing the cell surface expression of the receptor (SI Appendix, Fig. S3G). This is consistent with the reported constitutive activity of this mutant (33) (SI Appendix, Fig. S3H).
The mechanism of activation of the CaSR remains largely unknown (8). Crystal structures of the isolated CaSR ECD revealed that the lower lobes of the VFT come closer in the presence of agonists, leading to a close contact between the CRDs (19). To mimic activation-induced proximity of CRDs, we created a disulfide cross-linking of the two CRDs, as reported for mGlu2 receptor (34). The mutation of Pro569 into Cys led to a largely reduced FRET signal (Fig. 1J) despite a normal cell surface expression (SI Appendix, Fig. S3G). This mutation also induced strong constitutive activity (SI Appendix, Fig. S3H), consistent with the stabilization of the receptor in an active state, likely resulting from the cross-linking of the two CRDs. These data are consistent with Pro569 being at the CRD interface in the active ECD structure of the CaSR (19). Interestingly, Ca2+ can still further decrease the FRET signal (Fig. 1J), an effect that may be due to a fraction of receptors not being cross-linked, or alternatively, that cross-linking did not stabilize the receptor in its fully active state.
FRET Sensor Unravels the Rearrangement of the CaSR Dimer Interface during Activation.
We used the FRET sensor to investigate the changes in the 7TM dimer interface during the activation of the CaSR by a disulfide cross-linking approach, as recently reported for the mGlu (22, 35) and the GABAB (36) receptors (Fig. 2 A and B). We speculated that locking the active state 7TM interface should result in a lower basal FRET, while locking the inactive interface should limit the Ca2+-induced FRET change (Fig. 2C). We screened positions in TM4, TM5, TM6, and TM7, as these transmembrane helices were involved in the interface of other class C receptors (22, 35, 36). After copper phenanthroline (CuP) treatment to favor disulfide cross-linking between the introduced Cys residues, we observed a low FRET signal relative to control for six mutants in TM6 (I822C6.54, P823C6.55, A824C6.56, A826C6.58, S827C6.59, and T828C6.60) (Fig. 2C), but not for other positions in TM6 and in the other TMs (Fig. 2C and SI Appendix, Fig. S4 A and B). In contrast, for some mutants in TM4 and TM5 (V740C4.48, I741C4.49, Y744C4.52, T745C4.53, and M771C5.38), CuP treatment resulted in a decrease in the Ca2+ effect, suggesting that these mutations prevent the full rearrangement of the ECD dimer induced by the agonist, or alternatively, that a fraction of the receptors can no longer reach an active state (Fig. 2C). No such effect on the Ca2+-induced signal was observed with other cysteine mutants in these TMs (SI Appendix, Fig. S4A), as well as in TM6 and TM7 (Fig. 2C and SI Appendix, Fig. S4B). This indicates that TM4s and TM5s form the resting interface of the CaSR. All mutants were well expressed on the cell surface compared to the wild-type (WT) receptor (SI Appendix, Fig. S4 C and D).
Fig. 2.
The 7TM interface rearrangement is revealed by cysteine cross-linking and FRET. (A) Schematic representation of CaSR WT, mutant C129A-C131A (CACA, to remove the endogenous disulfide bonds between the two VFTs of CaSR dimer) and 7TM cysteine mutants with CACA background. (B) A 3D model of the CaSR 7TM in lateral and top view. Residues substituted by cysteine are highlighted as yellow spheres (α carbon), and the well cross-linked ones are highlighted in red. (C) Cysteine cross-linked mutants screened by TR-FRET in the absence or presence of 20 mM CaCl2 with and without CuP treatment. Data are mean ± SEM of at least three independent experiments performed in triplicates and normalized to WT (data with and without CuP are normalized separately). Data are analyzed using two-way ANOVA with Tukey’s multiple comparisons test to determine significance within each mutant group, with ****P ≤ 0.0001 and **P ≤ 0.01. (D) Analysis of cell surface CaSR subunits of the cysteine mutants (CACA as control) in SDS/PAGE experiments under nonreducing conditions, after treatment (+) or without treatment (−) with CuP. Changes of dimer ratio induced by CuP treatment for WT, the CACA control, and every indicated mutant are quantified and shown. Quantitative data are mean ± SEM of at least four independent experiments (n = 4 to 12) while the blot for each mutant is representative of one of these experiments. Data are analyzed using one-way ANOVA with Dunnett’s multiple comparisons test to determine significance (compared with CACA control), with ****P ≤ 0.0001, **P ≤ 0.01, and ns P > 0.05. (E) IP1 accumulation for WT and the indicated TM6 mutants after treatment (+) or without treatment (−) with CuP, in the absence or presence of 20 mM CaCl2. Data are mean ± SEM of at least three independent experiments performed in triplicates and normalized to WT (data with or without CuP are normalized separately). Two-way ANOVA with Tukey’s multiple comparisons test within each mutant group, with ****P ≤ 0.0001. (F) Model highlighting the TMs involved in the dimerization of CaSR in the resting state and in the active state.
We have verified that both resting and active interfaces were cross-linked by blot analysis of the SNAP-CaSR subunits (Fig. 2D). Cell surface SNAP-tagged CaSR constructs were covalently labeled with the cell-impermeant fluorescent substrate SNAP-Surface 649, and its signal was used as the readout of the blots, as previously reported (35). The CaSR WT dimer is covalently linked by disulfide bridges between the two VFTs, involving two conserved cysteines (Cys129 and Cys131), but that are not required for receptor assembly and activity (37, 38). First, we mutated these cysteines into alanine in a construct named CaSRCACA (Fig. 2A). As expected, this construct migrated mostly as a monomer in nonreducing conditions, in contrast to WT CaSR that migrated as a dimer (Fig. 2D). We then analyzed whether the Cys residues introduced in the TM could cross-link the CaSRCACA. The efficiency of cross-linking between the two subunits induced by CuP was quantified by the change in the dimer signal to the total quantity of the CaSR subunit detected on the blots (Fig. 2D). The results revealed efficient cross-linking when Cys was introduced in TM4, 5, or 6. As a negative control, no such cross-linking was observed with the mutant V737C4.45 (SI Appendix, Fig. S4E), a site in TM4, which cannot be cross-linked in agreement with the FRET results (SI Appendix, Fig. S4A). These data show that TM4, 5, and 6 likely constitute the CaSR dimer interface. Finally, we have confirmed that the TM6 dimer interface corresponds to the active state, as stabilizing this interface with a cysteine cross-linking at residues Ala8246.56 or Thr8286.60 leads to a constitutively active receptor (Fig. 2E).
Altogether, our results revealed a relative rearrangement between the two 7TMs during activation. While TM4-5 of each subunit faces each other in the inactive state, a TM6-TM6 contact occurs in the active state of the dimer (Fig. 2F and SI Appendix, Fig. S4F). This movement is then similar to that proposed for other class C GPCRs (22, 35, 36) and is consistent with the inactive and active-like structures of mGlu5 (22) and the inactive and active states of GABAB (25, 26).
Ambient l-Amino Acids Are Pure PAMs of CaSR.
Some l-AAs, specifically aromatic ones, are known to regulate CaSR activity (6). The binding site of the l-AAs in the VFT domain was found to be equivalent to the glutamate binding site in mGluRs, as revealed by site-directed mutagenesis (39, 40) and the crystal structures of the CaSR VFT dimer (19, 20). However, the exact role of l-AAs in the activation process of the CaSR remains elusive, as the CaSR function has always been studied in cellular assays, and thus in the presence of unknown concentrations of l-AAs (41). Probably due to these ambient l-AAs, l-Phe produced a modest, but statistically significant PAM effect measured either with functional assays (SI Appendix, Fig. S5 A and B), or with our FRET sensor (SI Appendix, Fig. S5C) in living cells.
To be able to perfectly control the ambient l-AA concentration, we established a cell-free assay for the CaSR based on membranes containing our TR-FRET-based sensor. The sensor was functional (Fig. 3 A–C), although agonist potencies were slightly better in living cells than in membranes (Fig. 3E). This may potentially result from a loss of bound l-AAs in the CaSR during membrane preparations.
Fig. 3.
Allosteric modulation by l-AA is clarified with a cell-free assay. (A) Cartoon illustrating the development of FRET-based CaSR biosensor in a cell-free assay based on cellular membrane preparations as indicated. (B) FRET signal measured on nondialyzed membranes with the indicated ligands. Data are mean ± SEM of at least three independent experiments performed in triplicates and normalized to the maximum response of CaCl2. (C) Correlation between the FRET potencies (pEC50) of the indicated agonists determined on cells and nondialyzed membranes. (D) FRET measurement performed with CaCl2 on nondialyzed and dialyzed membranes in the absence or presence of 10 mM l-Phe. Data are mean ± SEM of at least three independent experiments performed in triplicates and normalized to the basal of control and the maximum response of l-Phe. (E) FRET potencies (pEC50) of calcium on cells and on nondialyzed (−) or dialyzed (+) membranes in the absence or presence of 10 mM l-Phe. Data are mean ± SEM from at least eight independent experiments (n = 8 to 24). Two-way ANOVA with Tukey’s multiple comparisons, with ****P ≤ 0.0001, ***P ≤ 0.001, *P ≤ 0.05, and ns P > 0.05. (F) Basal FRET in the presence of the indicated l-AA at 10 mM (for Tyr-1 mM is used due to low solubility) or 10 μM TNCA. Data are mean ± SEM of at least three independent experiments (n = 3 to 13) performed in triplicates and normalized to the control. One-way ANOVA with Dunnett’s multiple comparisons test (compared with control) with ****P ≤ 0.0001, *P ≤ 0.05, and ns P > 0.05. (G) FRET potencies (pEC50) of calcium on dialyzed membranes in the presence of the indicated amino acid (same concentrations as in F). Data are mean ± SEM from at least three independent experiments (n = 3 to 13). One-way ANOVA with Dunnett’s multiple comparisons test (compared with control) with ****P ≤ 0.0001 and ns P > 0.05. (H) FRET signal change induced by the indicated l-AA performed on dialyzed membranes in the presence of 5 mM CaCl2. Data are mean ± SEM of at least three independent experiments performed in triplicates. Data are normalized to the basal conditions (5 mM CaCl2 without l-AA) and the maximum response induced by l-AAs.
To completely remove any l-AAs, membranes were dialyzed, and under such conditions, Ca2+ potency was significantly lower, but it induced a full rearrangement of the ECD, indicating that l-AAs are not required for Ca2+ to fully activate CaSR (Fig. 3 D and E). As expected, the addition of l-AAs such as l-Phe restored the high CaCl2 potency measured in cells (Fig. 3 D and E). As a control, d-Phe had no effect on both nondialyzed and dialyzed membranes (SI Appendix, Fig. S5 D and E), consistent with previous studies (6). As an additional control, NPS R-568 induced similar potency changes of CaCl2 in nondialyzed and dialyzed membranes consistent, with the absence of the ambient NPS R-568-like compound (SI Appendix, Fig. S5 D and E).
We then determined the effect of all 20 natural l-AAs at 10 mM (except l-Tyr at 1 mM) on these dialyzed membranes (Fig. 3 F and G and SI Appendix, Fig. S6). In the absence of calcium, most l-AAs did not induce a significant decrease in FRET, except for l-Cys (Fig. 3F and SI Appendix, Fig. S6). We could not exclude that slight basal FRET change in the presence of l-Cys as well as l-Leu and l-Met, might be due to fluorescent quenching or some effects unrelated to receptor conformation change (Fig. 3F). This shows that l-AAs have no intrinsic capacity to stabilize the active state of the CaSR in the absence of calcium. However, most l-AAs had a significant PAM effect at 10 mM, as revealed by the increased calcium potency, except l-Leu, l-Asp, l-Lys, and l-Pro (Fig. 3G). The aromatic l-AAs have the strongest PAM effects, as previously reported (6). The potency of each l-AA was determined in the presence of 5 mM CaCl2 (Fig. 3H and SI Appendix, Fig. S7), at which concentration l-AAs showed the maximum PAM effects. Aromatic l-AAs are the most potent, with EC50 values ranging from less than 100 µM (l-Trp and l-Tyr) to less than 1 mM (l-Phe and l-His). Of note, the l-Trp derivative TNCA (l-1,2,3,4-tetrahydronorharman-3-carboxylic acid) observed in the CaSR structure (20) displayed the highest potency among all l-AAs tested (Fig. 3 G and H and SI Appendix, Fig. S5F). This high potency (less than 100 nM) likely explains why this compound was copurified with the CaSR from HEK293 cells (20). Other nonaromatic l-AAs displayed potencies of ∼1 mM (l-Ala, l-Gln, l-Glu, l-Ile, l-Ser, l-Thr, and l-Val) to more than 10 mM (SI Appendix, Fig. S7).
A Genetic Mutation Shows a Stronger PAM Effect of l-AAs.
Our FRET biosensor enables the precise investigation of the molecular basis of genetic mutations in the action of l-AAs on CaSR. We studied the genetic mutation E297D, responsible for the gain of function in autosomal dominant hypocalcemia (42). Glu297 is part of the l-AA binding site in the crystal structures (19, 20) and was proposed to be involved in Ca2+ binding (42–44). In the cellular format, Ca2+ had a higher potency for the mutant compared to WT (SI Appendix, Fig. S8A), that was lost in nondialyzed membranes, where its potency is similar to the WT receptor (SI Appendix, Fig. S8C). The simplest explanation is that the E297D mutant has a higher affinity for some l-AAs, such that the endogenous l-AA concentration in the vicinity of the living cells is sufficient to almost maximally increase Ca2+ potency. This ambient l-AA concentration is expected to be lower in the membrane preparation, leading to a loss of this effect on the E297D mutant, making it similar to the WT receptor. In agreement with this proposal, the addition of l-Phe in the assay restored the high Ca2+ potency (SI Appendix, Fig. S8C). This is further demonstrated after membrane dialysis, where the E297D mutant behaves as the WT receptor (SI Appendix, Fig. S8B). These data suggested that this gain-of-function mutation results from a more efficacious PAM effect of l-AAs.
Chloride Ions Are PAMs at CaSR.
The structure of CaSR ECD in the active state (Protein Data Bank [PDB] 5FBK) (20) revealed three possible chloride binding sites (sites b, c, and g; Fig. 4A and SI Appendix, Fig. S1A). As Cl− ions were recently found to allosterically regulate most mGluRs (41, 45, 46), we investigated whether they could have any effect on the CaSR. The TR-FRET assay was performed in a gluconate buffer containing no chloride ions (0 mM Cl− buffer, Cl− being replaced by gluconate), gluconate having no effect on CaSR activity (SI Appendix, Fig. S9A). The main interest of gluconate, a small molecule, is to keep the negative charge of chloride but to be sure it cannot mimic a chloride effect by binding to the chloride site, due to its large size. Calcium gluconate induced a large decrease in FRET, indicating that Ca2+ induced rearrangement of the CaSR ECD in the absence of Cl−, although with a lower potency (Fig. 4B and SI Appendix, Fig. S9B). Chloride ions enhanced the Ca2+ effect by largely increasing its potency, while having no effect on their own, revealing a pure PAM action of Cl− up to its physiological concentration (larger than 100 mM) (Fig. 4B). Similar results were obtained in Ca2+i release assays (Fig. 4C).
Fig. 4.
Allosteric modulation induced by chloride ions in CaSR VFT. (A) Three chloride binding sites were reported in the CaSR structure (as shown in PDB 5FBK, sites b, c, and g refer to SI Appendix, Fig. S1). (B and C) FRET measurement (B) and Ca2+i release (C) for calcium gluconate on CaSR performed in a buffer with the indicated concentrations of chloride ions. Either Ca2+ concentration (Left) or Cl− concentration (in buffer, Right) is used as the x axis. Data are mean ± SEM of three independent experiments performed in triplicates and normalized to the maximum response in the buffer with the highest Cl− concentration.
We then investigated the functional effect of these three potential chloride binding sites on CaSR activity by site-directed mutagenesis (SI Appendix, Fig. S9 C–E). Sites b and c are proposed to be Ca2+ binding sites in another active conformation of CaSR (PDB 5K5S) (SI Appendix, Fig. S1). Site b was also proposed to bind calcium in the resting state (PDB 5K5T). Site b is the most conserved Cl− binding site in mGluRs (46) and other class C GPCRs such as the taste receptors T1Rs (PDB 5X2P) (47). Mutation of the most conserved residues of this site (SI Appendix, Fig. S10A), T100A, strongly impaired the activation of the receptor by calcium. In contrast, the mutation T100E did not impair the activity of the receptor, consistent with the distal carboxylate group of Glu100, mimicking a chloride ion (46) (SI Appendix, Fig. S9C). These two mutations produced similar effects to the same mutations in the mGlu4 receptor (46), suggesting that this site could be a chloride binding site important for receptor function. In contrast, site c is composed of nonconserved residues (Arg66, Ser302, and Ser303) and their mutations do not strongly impair receptor activity (SI Appendix, Fig. S9D), suggesting that this site is not important for calcium effects on CaSR, but it could be a site responsible for PAM action of Cl−. Finally, site g exists only in this structure, but it is most probably a structural binding site for chloride, and as such was not studied further except through a mutation that has no effect (SI Appendix, Fig. S9E).
Functional Calcium Binding Sites Near l-AAs at CaSR.
As already mentioned, several Ca2+ binding sites have been proposed based on the crystal structures of the CaSR dimer (19, 20), but none of them have been firmly validated, and discrepancies exist between the two studies (SI Appendix, Fig. S1).
The main Ca2+ site was proposed to be located between the lower lobes (lobe 2) in the VFT dimer interface, and other cations (magnesium, gadolinium) have been proposed to also bind at this interface (see sites d through f) (Fig. 5A and SI Appendix, Fig. S1) (19, 20, 48). It is a region composed of highly negatively charged residues with numerous Glu and Asp residues (Fig. 5A and SI Appendix, Figs. S10B and S11A) and has been reported to stabilize the active state of other class C GPCRs by binding cations that neutralize these negative repulsive electrostatic charges (49). To investigate the importance of this interface for calcium activation, we have mutated all negatively charged residues including residues proposed to bind calcium, magnesium, or even gadolinium in the CaSR structures (Fig. 5 A and B and SI Appendix, Fig. S11 B–E). These single and multiple mutants were well activated by calcium, suggesting that the activating binding site for calcium is not at this interface.
Fig. 5.
Binding of two calcium ions nearby l-AA stabilizes the active state. (A) Cartoon illustrating the possible calcium binding at the lobe 2 interface which was previously proposed to be important for receptor activation. (B) Ca2+i release for the indicated mutants in this lobe 2 interface. (C) Possible Ca2+ binding in the l-AA binding pocket. (D–F) Proposed Ca2+ binding site 1 in the VFT hinge as illustrated by the cartoon (D), the 3D model of this site based on the crystal structure of the VFT (PDB 5K5S) (E), and Ca2+i release data for the indicated mutant in this site (F). Ca2+ is proposed to be bound to S170, D190, Q193, Y218, E297, and one water molecule found in the crystal structure. (G–I) Similar analysis for the proposed calcium binding site 2 in the VFT adjacent to l-AA, and Ca2+i release data for the indicated mutants. Ca2+ is proposed to be bound to the lobe 2 residues D216, S272, D275, and one water molecule found in the crystal structure (bridging this Ca2+ and bound l-Trp). (J–L) Combination of the two functional calcium binding sites 1 and 2 adjacent to the bound l-AA, top view of the l-AA surrounded by the two Ca2+ and Ca2+i release data for the indicated mutants. In the 3D model, interactions are shown as dashed lines (green for H-bonds, gray for metal bonds). Data in B, F, I, and L are mean ± SEM of at least three independent experiments performed in triplicates and normalized to WT. Mock indicates mock transfected cells with empty pRK5 vector.
Among the other monatomic ion binding sites found in the crystal structures (SI Appendix, Fig. S1 A and B), sites b and c have low probability to bind functional Ca2+, as they likely bind Cl−, as shown above. In addition, site a has also low probability to bind cations important for CaSR activation, since it is formed by the polypeptide backbone (SI Appendix, Fig. S11 F and G) and it is a conserved structural binding site for cations as reported in mGluRs (50) and a fish taste T1R2/T1R3 receptor (47) (SI Appendix, Fig. S11H).
Since l-AAs have strong PAM activity, and calcium was proposed to bind near the l-AA binding pocket in the receptor (20, 42, 43), we then explored this possibility for the Ca2+ binding site (Fig. 5C). The first possible site (site 1, Fig. 5 D and E) is located close to the hinge of the VFT. At this site, previous computational studies described a calcium ion binding to the conserved network of residues found in class C GPCRs activated by amino acids (e.g., mGluRs, DmXR, T1Rs, OR5.24, and GPRC6A) (42, 48). This network makes a signature motif that interacts with the amino acid moiety of the various agonists (51) (SI Appendix, Fig. S10A). However, none of the CaSR VFT crystal structures displayed an ion at such a position. Instead, a water molecule is reported in the two crystal structures with sufficient resolution (5FBK and 5K5S) (19, 20). Changing this water molecule to a calcium ion and minimizing the binding residues, revealed the interactions previously computed (Ser170, Asp190, Gln193, Tyr218, and Glu297; Fig. 5E) (42, 48). Indeed, the electronic density radii of a calcium ion and oxygen of a water molecule are close (http://abulafia.mt.ic.ac.uk/shannon/radius.php). Accordingly, we have validated this site 1 by site-directed mutagenesis and functional assays. Among the five mutants of the residues predicted to bind calcium, three (S170A, D190A, and Y218A) largely impaired the Ca2+ effect (Fig. 5F), consistent with Silve et al. (42). Interestingly, the Hill number of Ca2+ on these mutants (S170A, nH = 1.44 ± 0.18; D190A, nH = 1.57 ± 0.19; and Y218A, nH = 1.09 ± 0.19) was much lower than that on the WT (nH = 2.33 ± 0.07). This suggests that one calcium ion binds to site 1. Due to the dimeric nature of the CaSR, there are two sites 1 per receptor, which may explain why the nH of the mutant is still higher than 1. Among the residues binding the calcium ion, Asp190 and Glu297 can establish strong ionic interactions because of their negatively charged side chains. Additionally, Asp190 is found in the hinge of the VFT where the closing movement is initiated; this supports its major role. The mutations S170 or Y218 to Ala had even a stronger effect but it is difficult to provide an explanation, as all four residues are well-conserved in class C VFTs (51).
The highly cooperative nature of Ca2+ activation (nH > 2) suggests the existence of at least a second site that is important for receptor activation (Fig. 5G). Zhang et al. suggested that the electron density surrounded by Asp216, Ser272, Asp275, and a coordinating water molecule could be a magnesium ion (Mg2+) (20). They opted for a highly ordered water molecule instead of a metal cation. A similar water molecule is found in all three structures of the closed CaSR VFT (PDB 5FBK, 5FBH, and 5K5S) (19, 20). We propose that a calcium ion may be found in place of this water molecule, although this water molecule could be in dynamic equilibrium with Ca2+. Binding of calcium would provide a better stabilization of the closed VFT than a water molecule, since the Ca2+ ion can make up to eight bounds and a water molecule only four bounds. Thus, we implemented the change in the three-dimensional (3D) structure 5FBK and similarly in 5K5S. We observed interactions between calcium and Asp216, Ser272, Asp275, and a coordinating water molecule (Fig. 5H). In order to validate our model, we mutated these three residues to alanine at site 2. Mutations D216A strongly impaired the activation of the receptor by calcium (Fig. 5I), and the Hill number is decreased (nH = 1.66 ± 0.25). This supports the idea that one calcium ion could bind at site 2. Finally, when site 1 and 2 mutations were combined in the double mutant D190A-D216A (Fig. 5 J–L and SI Appendix, Fig. S12A), the receptor activation by Ca2+ was strongly impaired, in agreement with the additivity of the effect of these single mutants (Fig. 5L). We have verified that all of the mutants were correctly expressed at the cell surface by ELISA (SI Appendix, Fig. S12D). Notably, we did not use the FRET CaSR biosensor to analyze calcium binding, as the mutations already impaired the conformational equilibrium of ECD. Indeed, we have shown that these mutations reduced the basal FRET signal of the CaSR (SI Appendix, Fig. S12B), indicating they favor the rearrangement of the VFT dimer toward an active-like conformation. We excluded that these mutations impaired receptor folding since they did not abolish agonist-induced CaSR rearrangement in the TR-FRET assay (SI Appendix, Fig. S12B) and allosteric modulation by the NPS R-568 (SI Appendix, Fig. S12C). In addition, mutations did not impair cell surface expression of the CaSR (SI Appendix, Fig. S12D). Thus we proposed that these mutants are relevant to draw our conclusions on the calcium binding sites.
Altogether, our results suggest that there are two calcium binding sites in the l-AA binding pocket that are important for the activation of CaSR (Fig. 6 A and B). Eventually, both sites 1 and 2 were validated at the website CheckMyMetal, the metal binding site validation server (52, 53). Both calcium ions are on either side of the l-AA and interact indirectly with it (Fig. 5 E, H, and K). Ca2+ at site 1 interacts with l-AA through Ser170, Glu297, and Tyr218, while at site 2, calcium interacts with l-AA through one water molecule. Consistent with the possible physiological role of these Ca2+/l-AA interacting sites, a mixture of l-AAs at concentrations found in fasting human brain plasma nicely potentiates Ca2+-mediated responses in a physiological concentration range (Fig. 6C); but increasing the l-AA mix concentration, as observed after a protein-rich meal (54, 55), can further increase the effect of the physiological Ca2+ concentration (Fig. 6D).
Fig. 6.
Model for the activation of CaSR. (A) A 3D model of two possible functional calcium sites 1 and 2 near the bound l-AA based on the crystal structure of the VFT (PDB 5K5S). (B) VFT close state is proposed to be stabilized by calcium ions in the presence of ambient l-AA (cell-based conditions), but also by calcium ions alone in the absence of l-AA (cell-free conditions) during activation. The ambient l-AAs bound to CaSR VFT contribute to the high calcium potency and enable the receptor to sense low concentrations of calcium ions. But this high sensitivity to calcium is reduced when l-AA is lost. (C) FRET measurement performed with CaCl2 on dialyzed membranes in the absence or presence of one-fold l-AA mixture containing l-AA concentrations mimicking the human fasting plasma. Data are mean ± SEM of at least three independent experiments performed in triplicates and normalized to the basal of control and the maximum response of l-AA mixture. (D) FRET signal change induced by different folds of the l-AA mixture (C) performed in dialyzed membranes in the presence of CaCl2. Data are mean ± SEM of at least three independent experiments performed in triplicates. Data are normalized to the basal (without Ca2+ or l-AA) and the maximum response induced by Ca2+ in the presence of l-AA mixture. The vertical dotted line represents the related total concentration 2.82 mM of l-AAs used in one-fold l-AA mixture. (E) Molecular mechanism of activation of the CaSR upon l-AA and calcium binding. Binding of calcium ions in the VFT binding pocket most probably occupied by l-AA in physiological conditions, is expected to stabilize VFT closure and their relative rearrangement. Then it would induce CRD interactions and 7TM interface reorientation through allosteric propagation of the conformation changes. In the active state, TM6s will be at the dimer interface, a conformation required to stabilize at least one of the 7TMs in the active state for G protein activation.
Discussion
CaSR is a prototypical nutrient receptor regulated by various signaling compounds, including ions (Ca2+ and Mg2+ as activators, while SO42− and PO43− act as negative allosteric modulators [NAMs]) (19, 56), l-AAs, and polyamines like spermine (57). Structural studies also revealed that CaSR can bind Cl−. In the present study, we investigated how such structurally different compounds regulate this receptor. We first analyzed the conformational changes associated with receptor activation at the level of the VFT, CRD, and 7TM domains using a FRET-based approach together with mutagenesis studies. This allowed us to validate a CaSR biosensor that was used to examine the action of various ligands in a cell-free and nutrient-controlled environment. We show that Ca2+ alone can fully stabilize the active state of the CaSR by inducing VFT closure, and we identified two important sites for this effect. In contrast, most l-AAs have no effect on their own, but enhance Ca2+ potency at this receptor, acting then as pure PAMs, rather than coagonists. We also revealed that chloride ions also act as PAMs of CaSR.
We show that SNAP-tag fusion at the N terminus of the CaSR subunits allowed a direct analysis of the conformational change occurring during receptor activation. This can be recorded through TR-FRET measurements after covalent labeling of the subunits with SNAP substrates carrying compatible fluorophores. These data reveal a similar change in the VFT orientation of the CaSR compared to mGluRs upon activation (58) (Fig. 6E). This is in contrast to the proposed structures for the resting and active states of the CaSR (19), as the relative orientation of the VFTs is similar in both proposed states (Fig. 1B). Our data suggest a different conformation for the resting CaSR, likely closer to that observed with the resting mGluRs such as the full-length mGlu5 structure (22). The CaSR active form predicted a close contact between the CRDs (19) that we validated by cross-linking experiments (Fig. 6E). Moreover, the sensor was also helpful in identifying positions in the 7TM domain that can be cross-linked to lock the receptor either in the resting high FRET state or in the active low FRET state. Such analysis suggests a similar movement of the 7TM domains as previously reported for mGluR2 (35) or observed in the mGluR5 cryogenic electron microscopy-EM structures (22). Indeed, the TM4 and TM5 of 7TM domains face each other in the resting state, while TM6s appear to be in close contact in the active state (Fig. 6E). Whether the 7TM domains contact each other in the inactive CaSR state is still questionable, as this is not the case in the resting mGlu5 structure (22), although TM4 and TM5 are indeed facing each other, allowing cross-linking to occur upon CuP treatment (35).
The use of the CaSR sensor allowed us to study its activation under controlled conditions, in the absence of Ca2+ or in the absence of l-AAs. This allowed us to demonstrate that Ca2+ alone was able to fully activate the receptor, while l-AAs at a concentration of 10 mM cannot, indicating that l-AAs are pure PAMs. This is in contrast to many class C GPCRs, including mGluRs, fish olfactory receptors such as zOlfCc1 (59) and OR5.24 (60), GPRC6A (61), the murine pheromone receptor mVmn2r1 (59), or the umami taste receptor (47) (including rat/mouse receptors) that can be directly activated by the l-AAs. This is even more surprising when one considers that the amino acid binding mode is very similar in all these receptors and involves the same residues interacting with the α-amino and α-carboxylic groups (51). However, we found that most l-AAs except for Leu, Asp, Lys, and Pro (at 10 mM), potentiated the effect of Ca2+ by increasing its potency, such that the active l-AA appears able to activate CaSR in the presence of low concentrations of Ca2+. This raises the question of whether some other class C GPCRs activated by l-AAs also require Ca2+ for activation. Indeed, many of these receptors are also regulated by Ca2+ (59, 61–63). Finally, why some l-AAs do not show a PAM effect on CaSR is speculative, it might be due to steric hindrance in the VFT that prevents some l-AAs to bind, such as their binding could be restored only when the VFT is mutated (64).
Structural studies revealed that chloride ions bound to the CaSR VFT at three sites. Our data show that, as observed with mGluRs, Cl− at physiological concentrations is a PAM of the CaSR, an effect that involves two binding sites corresponding to those identified in mGluRs (41, 46), further illustrating the similarity between these receptors. However, such an effect of chloride ions is unlikely to have any physiological effect, as their PAM effect is saturated at their physiological concentration, and it is not expected that plasma Cl− concentrations will change sufficiently to affect CaSR activity. Although it is speculative, we propose that site c might be responsible, at least in part, for the PAM effect of Cl−, by stabilizing the closed form of the VFT as l-AAs do, even though the effect of mutations in this site is weak. Indeed, site c involves residues from both lobe 1 (upper lobe) and lobe 2 (lower lobe) of the VFT and then Cl− binding at this site could stabilize the closed state of the VFT required for class C receptor activation (58). Binding of Cl− to site b has most probably a structural function, since this chloride is highly conserved in class C GPCRs (46) and it involves only residues of lobe 1. Thus it is difficult to interpret how this site could be associated with a PAM effect. Finally, we cannot exclude that additional chloride binding sites in CaSR ECD, but not yet identified, can play a role in the PAM effect of Cl−.
Although calcium ions appear to be the main and only direct activator of CaSR, it was surprising that its binding sites remained elusive, despite the solved structures of the CaSR ECD by two groups (19, 20). Surprisingly, mutation of the Ca2+ sites based on these structures did not affect Ca2+ activation of the receptor, indicating that even though Ca2+ may bind at those sites, it does not affect the activity of the CaSR. Another possible Ca2+ site was previously predicted by modeling and docking studies in the l-AA binding pocket (42, 43, 65), called site 1. The second site in this VFT binding pocket, site 2, was proposed to bind Mg2+ by Zhang et al. (20). Our data clearly suggest that site 1 and site 2 are responsible for CaSR activation by Ca2+. Mutating one of these sites resulted in a decreased Ca2+ effect, and most importantly, in a decreased nH, from 2.3 for the WT to ∼1.7 or below for the mutants, consistent with a decrease in the number of activating Ca2+ sites. The fact that nH remains significantly higher than 1 is also consistent with the dimeric nature of CaSR with a possible positive cooperativity between the subunits, as observed for the activation of mGluRs by glutamate (66). Notably, mutating both Ca2+ sites in each subunit results in a drastic decrease in Ca2+ activation, demonstrating the essential role of these two sites in CaSR activation. The low potency of Ca2+ for these sites, and the difficulty in assigning ions to specific densities in crystal structure (67), may explain why these two important sites have been missed when analyzing CaSR ECD structures.
Together, these data assist us to propose a model for how Ca2+ and l-AAs regulate CaSR activity. Ca2+ at site 1 interacts with residues close to the hinge region of the VFT, and contact residues from both lobes, thus, likely stabilizing the close active state of the VFT. Site 2 only involves residues from lobe 2 such that it is more difficult to imagine how Ca2+ binding at this site may be sufficient to activate the receptor, as observed when site 1 is mutated. It is possible that Ca2+ neutralizes negative charges, such as that carried by D216, allowing the closure of the VFT, or that networks involving water molecules participate in stabilizing the closed VFT. Since l-AAs do not activate CaSR on their own, it is questionable whether they bind to the VFT in the absence of Ca2+. However, because of the number of interactions they make with lobe 1 residues, we think they do. It is possible that they cannot stabilize the closed active VFT because of the repulsion of lobe 2, due to the negative charge of D216. Only when this charge is neutralized with Ca2+ bound at site 2 can the VFT get close. This residue may be responsible for the activation difference between the CaSR and other class C receptors that are activated by l-AAs.
Taken together, our data clarify the mode of action of Ca2+ and l-AAs on CaSR. The question of course remains, however, whether the l-AA PAM effect is the result of the evolution of this receptor from l-AA-activated class C GPCRs such as the mGlu, the fish l-AA olfactory, or even the umami taste receptor, or whether such a l-AA effect on CaSR is of physiological importance. Indeed, our well-controlled assay clearly confirms and further elucidates that a l-AA mix, corresponding to that found in fasting human plasma, can potentiate the effect of physiological concentrations of Ca2+ on the CaSR. Notably, increasing this l-AA mix concentration, as observed after a protein-rich meal, further potentiates the Ca2+ response. It is therefore likely that the increase in l-AA plasma concentration after a meal (up to 30 mM) enhances the Ca2+ effect, leading to a decreased PTH secretion (6). Indeed, PTH plasma concentration is reduced after meals (54, 55). Whether this is only due to the allosteric control of CaSR by l-AAs or to other processes remains to be examined, but it is likely that this, at least, plays a role. In conclusion, our data illustrate how a receptor could integrate the information coming from various structurally different nutrients to generate an optimized cellular response.
Materials and Methods
Information on materials, transfection, cell surface quantification, inositol phosphate accumulation, Ca2+i release, cross-linking, molecular modeling, curve fitting, and data analysis is provided in SI Appendix.
FRET Measurements on Cells and Membranes.
Labeling and FRET measurements on cells were performed as described previously (21, 24). Membranes were prepared and dialyzed after labeling on cells. See SI Appendix for more details.
Supplementary Material
Acknowledgments
We thank the Arpège platform at the Institut de Génomique Fonctionnelle for providing facilities and technical support, Cisbio for providing reagents, and Jurriaan Zwier for FRET decay analysis. J.L. was supported by the Ministry of Science and Technology of China (Grant 2018YFA0507003), the National Natural Science Foundation of China (Grants 31420103909, 81720108031, 31721002, and 81872945), and the Program for Introducing Talents of Discipline to the Universities of the Ministry of Education (Grant B08029). P.R. and J.-P.P. were supported by the CNRS, the Institut National de la Santé et de la Recherche Médicale, and by grants from the Agence Nationale de la Recherche (ANR-09-BIOT-018-01) and the Fondation pour la Recherche Médicale (Equipe DEQ20170336747). F.A. is supported by the CNRS and the Science Ambassador Program from Dassault Systèmes BIOVIA.
Footnotes
The authors declare no competing interest.
This article is a PNAS Direct Submission.
This article contains supporting information online at https://www.pnas.org/lookup/suppl/doi:10.1073/pnas.1922231117/-/DCSupplemental.
Data Availability.
All data and associated protocols for this study are available in the main paper and SI Appendix. Materials may be requested to P.R.
References
- 1.Efeyan A., Comb W. C., Sabatini D. M., Nutrient-sensing mechanisms and pathways. Nature 517, 302–310 (2015). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 2.Hauser A. S., Attwood M. M., Rask-Andersen M., Schiöth H. B., Gloriam D. E., Trends in GPCR drug discovery: New agents, targets and indications. Nat. Rev. Drug Discov. 16, 829–842 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 3.Husted A. S., Trauelsen M., Rudenko O., Hjorth S. A., Schwartz T. W., GPCR-mediated signaling of metabolites. Cell Metab. 25, 777–796 (2017). [DOI] [PubMed] [Google Scholar]
- 4.Zarzycka B., Zaidi S. A., Roth B. L., Katritch V., Harnessing ion-binding sites for GPCR pharmacology. Pharmacol. Rev. 71, 571–595 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 5.Brown E. M., MacLeod R. J., Extracellular calcium sensing and extracellular calcium signaling. Physiol. Rev. 81, 239–297 (2001). [DOI] [PubMed] [Google Scholar]
- 6.Conigrave A. D., Quinn S. J., Brown E. M., L-amino acid sensing by the extracellular Ca2+-sensing receptor. Proc. Natl. Acad. Sci. U.S.A. 97, 4814–4819 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 7.Conigrave A. D., Quinn S. J., Brown E. M., Cooperative multi-modal sensing and therapeutic implications of the extracellular Ca(2+) sensing receptor. Trends Pharmacol. Sci. 21, 401–407 (2000). [DOI] [PubMed] [Google Scholar]
- 8.Leach K. et al., International Union of Basic and Clinical Pharmacology. CVIII. Calcium-sensing receptor nomenclature, pharmacology, and function. Pharmacol. Rev. 72, 558–604 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 9.Hannan F. M., Kallay E., Chang W., Brandi M. L., Thakker R. V., The calcium-sensing receptor in physiology and in calcitropic and noncalcitropic diseases. Nat. Rev. Endocrinol. 15, 33–51 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 10.Hu J., Spiegel A. M., Naturally occurring mutations of the extracellular Ca2+-sensing receptor: Implications for its structure and function. Trends Endocrinol. Metab. 14, 282–288 (2003). [DOI] [PubMed] [Google Scholar]
- 11.Makita N. et al., Cinacalcet corrects biased allosteric modulation of CaSR by AHH autoantibody. JCI Insight 4, e126449 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 12.Walter S. et al., Pharmacology of AMG 416 (Velcalcetide), a novel peptide agonist of the calcium-sensing receptor, for the treatment of secondary hyperparathyroidism in hemodialysis patients. J. Pharmacol. Exp. Ther. 346, 229–240 (2013). [DOI] [PubMed] [Google Scholar]
- 13.Alexander S. T. et al., Critical cysteine residues in both the calcium-sensing receptor and the allosteric activator AMG 416 underlie the mechanism of action. Mol. Pharmacol. 88, 853–865 (2015). [DOI] [PubMed] [Google Scholar]
- 14.Leach K. et al., Towards a structural understanding of allosteric drugs at the human calcium-sensing receptor. Cell Res. 26, 574–592 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 15.Nemeth E. F. et al., Pharmacodynamics of the type II calcimimetic compound cinacalcet HCl. J. Pharmacol. Exp. Ther. 308, 627–635 (2004). [DOI] [PubMed] [Google Scholar]
- 16.Kawata T. et al., A novel calcimimetic agent, evocalcet (MT-4580/KHK7580), suppresses the parathyroid cell function with little effect on the gastrointestinal tract or CYP isozymes in vivo and in vitro. PLoS One 13, e0195316 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 17.Kniazeff J., Prézeau L., Rondard P., Pin J. P., Goudet C., Dimers and beyond: The functional puzzles of class C GPCRs. Pharmacol. Ther. 130, 9–25 (2011). [DOI] [PubMed] [Google Scholar]
- 18.Zhang C. et al., Molecular basis of the extracellular ligands mediated signaling by the calcium sensing receptor. Front. Physiol. 7, 441 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 19.Geng Y. et al., Structural mechanism of ligand activation in human calcium-sensing receptor. eLife 5, e13662 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 20.Zhang C. et al., Structural basis for regulation of human calcium-sensing receptor by magnesium ions and an unexpected tryptophan derivative co-agonist. Sci. Adv. 2, e1600241 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 21.Doumazane E. et al., Illuminating the activation mechanisms and allosteric properties of metabotropic glutamate receptors. Proc. Natl. Acad. Sci. U.S.A. 110, E1416–E1425 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 22.Koehl A. et al., Structural insights into the activation of metabotropic glutamate receptors. Nature 566, 79–84 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 23.Levitz J. et al., Mechanism of assembly and cooperativity of homomeric and heteromeric metabotropic glutamate receptors. Neuron 92, 143–159 (2016). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 24.Scholler P. et al., HTS-compatible FRET-based conformational sensors clarify membrane receptor activation. Nat. Chem. Biol. 13, 372–380 (2017). [DOI] [PubMed] [Google Scholar]
- 25.Mao C. et al., Cryo-EM structures of inactive and active GABAB receptor. Cell Res. 30, 564–573 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 26.Shaye H. et al., Structural basis of the activation of a metabotropic GABA receptor. Nature, 10.1038/s41586-020-2408-4 (2020). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 27.Doumazane E. et al., A new approach to analyze cell surface protein complexes reveals specific heterodimeric metabotropic glutamate receptors. FASEB J. 25, 66–77 (2011). [DOI] [PubMed] [Google Scholar]
- 28.Lecat-Guillet N. et al., FRET-based sensors unravel activation and allosteric modulation of the GABAB receptor. Cell Chem. Biol. 24, 360–370 (2017). [DOI] [PubMed] [Google Scholar]
- 29.Nemeth E. F. et al., Calcimimetics with potent and selective activity on the parathyroid calcium receptor. Proc. Natl. Acad. Sci. U.S.A. 95, 4040–4045 (1998). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 30.Gowen M. et al., Antagonizing the parathyroid calcium receptor stimulates parathyroid hormone secretion and bone formation in osteopenic rats. J. Clin. Invest. 105, 1595–1604 (2000). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 31.Yao X. J. et al., The effect of ligand efficacy on the formation and stability of a GPCR-G protein complex. Proc. Natl. Acad. Sci. U.S.A. 106, 9501–9506 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 32.Sánchez-Fernández G. et al., Gαq signalling: The new and the old. Cell. Signal. 26, 833–848 (2014). [DOI] [PubMed] [Google Scholar]
- 33.Zhao X. M., Hauache O., Goldsmith P. K., Collins R., Spiegel A. M., A missense mutation in the seventh transmembrane domain constitutively activates the human Ca2+ receptor. FEBS Lett. 448, 180–184 (1999). [DOI] [PubMed] [Google Scholar]
- 34.Huang S. et al., Interdomain movements in metabotropic glutamate receptor activation. Proc. Natl. Acad. Sci. U.S.A. 108, 15480–15485 (2011). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 35.Xue L. et al., Major ligand-induced rearrangement of the heptahelical domain interface in a GPCR dimer. Nat. Chem. Biol. 11, 134–140 (2015). [DOI] [PubMed] [Google Scholar]
- 36.Xue L. et al., Rearrangement of the transmembrane domain interfaces associated with the activation of a GPCR hetero-oligomer. Nat. Commun. 10, 2765 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 37.Ray K. et al., Identification of the cysteine residues in the amino-terminal extracellular domain of the human Ca(2+) receptor critical for dimerization. Implications for function of monomeric Ca(2+) receptor. J. Biol. Chem. 274, 27642–27650 (1999). [DOI] [PubMed] [Google Scholar]
- 38.Zhang Z., Sun S., Quinn S. J., Brown E. M., Bai M., The extracellular calcium-sensing receptor dimerizes through multiple types of intermolecular interactions. J. Biol. Chem. 276, 5316–5322 (2001). [DOI] [PubMed] [Google Scholar]
- 39.Mun H. C. et al., The Venus Fly Trap domain of the extracellular Ca2+ -sensing receptor is required for L-amino acid sensing. J. Biol. Chem. 279, 51739–51744 (2004). [DOI] [PubMed] [Google Scholar]
- 40.Zhang Z. et al., Three adjacent serines in the extracellular domains of the CaR are required for L-amino acid-mediated potentiation of receptor function. J. Biol. Chem. 277, 33727–33735 (2002). [DOI] [PubMed] [Google Scholar]
- 41.Tora A. S. et al., Chloride ions stabilize the glutamate-induced active state of the metabotropic glutamate receptor 3. Neuropharmacology 140, 275–286 (2018). [DOI] [PubMed] [Google Scholar]
- 42.Silve C. et al., Delineating a Ca2+ binding pocket within the venus flytrap module of the human calcium-sensing receptor. J. Biol. Chem. 280, 37917–37923 (2005). [DOI] [PubMed] [Google Scholar]
- 43.Huang Y. et al., Identification and dissection of Ca(2+)-binding sites in the extracellular domain of Ca(2+)-sensing receptor. J. Biol. Chem. 282, 19000–19010 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 44.Zhang C. et al., Direct determination of multiple ligand interactions with the extracellular domain of the calcium-sensing receptor. J. Biol. Chem. 289, 33529–33542 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 45.DiRaddo J. O. et al., Chloride is an agonist of group II and III metabotropic glutamate receptors. Mol. Pharmacol. 88, 450–459 (2015). [DOI] [PubMed] [Google Scholar]
- 46.Tora A. S. et al., Allosteric modulation of metabotropic glutamate receptors by chloride ions. FASEB J. 29, 4174–4188 (2015). [DOI] [PubMed] [Google Scholar]
- 47.Nuemket N. et al., Structural basis for perception of diverse chemical substances by T1r taste receptors. Nat. Commun. 8, 15530 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 48.Zhang C. et al., Identification of an L-phenylalanine binding site enhancing the cooperative responses of the calcium-sensing receptor to calcium. J. Biol. Chem. 289, 5296–5309 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 49.Tsuchiya D., Kunishima N., Kamiya N., Jingami H., Morikawa K., Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc. Natl. Acad. Sci. U.S.A. 99, 2660–2665 (2002). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 50.Kunishima N. et al., Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 407, 971–977 (2000). [DOI] [PubMed] [Google Scholar]
- 51.Acher F. C., Bertrand H. O., Amino acid recognition by Venus flytrap domains is encoded in an 8-residue motif. Biopolymers 80, 357–366 (2005). [DOI] [PubMed] [Google Scholar]
- 52.Handing K. B. et al., Characterizing metal-binding sites in proteins with X-ray crystallography. Nat. Protoc. 13, 1062–1090 (2018). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 53.Zheng H. et al., Validation of metal-binding sites in macromolecular structures with the CheckMyMetal web server. Nat. Protoc. 9, 156–170 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 54.Brown A. J., Koch M. J., Coyne D. W., Oral feeding acutely down-regulates serum PTH in hemodialysis patients. Nephron Clin. Pract. 103, c106–c113 (2006). [DOI] [PubMed] [Google Scholar]
- 55.Sethi R. et al., Effect of meal on serum parathyroid hormone and calcitonin: Possible role of secretin. J. Clin. Endocrinol. Metab. 56, 549–552 (1983). [DOI] [PubMed] [Google Scholar]
- 56.Centeno P. P. et al., Phosphate acts directly on the calcium-sensing receptor to stimulate parathyroid hormone secretion. Nat. Commun. 10, 4693 (2019). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 57.Quinn S. J. et al., The Ca2+-sensing receptor: A target for polyamines. Am. J. Physiol. 273, C1315–C1323 (1997). [DOI] [PubMed] [Google Scholar]
- 58.Rondard P., Pin J. P., Dynamics and modulation of metabotropic glutamate receptors. Curr. Opin. Pharmacol. 20, 95–101 (2015). [DOI] [PubMed] [Google Scholar]
- 59.DeMaria S. et al., Role of a ubiquitously expressed receptor in the vertebrate olfactory system. J. Neurosci. 33, 15235–15247 (2013). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 60.Speca D. J. et al., Functional identification of a goldfish odorant receptor. Neuron 23, 487–498 (1999). [DOI] [PubMed] [Google Scholar]
- 61.Christiansen B., Hansen K. B., Wellendorph P., Bräuner-Osborne H., Pharmacological characterization of mouse GPRC6A, an L-α-amino-acid receptor modulated by divalent cations. Br. J. Pharmacol. 150, 798–807 (2007). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 62.Tordoff M. G., Alarcón L. K., Valmeki S., Jiang P., T1R3: A human calcium taste receptor. Sci. Rep. 2, 496 (2012). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 63.Zou J., Jiang J. Y., Yang J. J., Molecular basis for modulation of metabotropic glutamate receptors and their drug actions by extracellular Ca2. Int. J. Mol. Sci. 18, 672 (2017). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 64.Planamente S. et al., A conserved mechanism of GABA binding and antagonism is revealed by structure-function analysis of the periplasmic binding protein Atu2422 in Agrobacterium tumefaciens. J. Biol. Chem. 285, 30294–30303 (2010). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 65.Huang Y. et al., Multiple Ca(2+)-binding sites in the extracellular domain of the Ca(2+)-sensing receptor corresponding to cooperative Ca(2+) response. Biochemistry 48, 388–398 (2009). [DOI] [PMC free article] [PubMed] [Google Scholar]
- 66.Kniazeff J. et al., Closed state of both binding domains of homodimeric mGlu receptors is required for full activity. Nat. Struct. Mol. Biol. 11, 706–713 (2004). [DOI] [PubMed] [Google Scholar]
- 67.Echols N. et al., Automated identification of elemental ions in macromolecular crystal structures. Acta Crystallogr. D Biol. Crystallogr. 70, 1104–1114 (2014). [DOI] [PMC free article] [PubMed] [Google Scholar]
Associated Data
This section collects any data citations, data availability statements, or supplementary materials included in this article.
Supplementary Materials
Data Availability Statement
All data and associated protocols for this study are available in the main paper and SI Appendix. Materials may be requested to P.R.






